Nidek has announced that the FDA has issued 510(k) clearance for the YC-200 Ophthalmic YAG Laser System. The YC-200 includes the S plus model for Selective Laser Trabeculoplasty (SLT). With FDA clearance, the YC-200 and YC-200 S plus are now commercially available in the United States.
The YC-200/YC-200 S plus is the successor to the YC-1800 laser. The YC-200/YC-200 S plus laser builds on the popularity and technology of the YC-1800 by incorporating newer optical designs, engineering and software advances to ensure precise targeting of pathology, while ensuring efficacious treatments and enhancing surgeon visualization of laser delivery, according to a company news release.
The optical system improvements optimize resolution and contrast. An expanded focal depth and natural-colored bright LED illumination provide unparalleled views of the pathology and treatment. Two rotatable aiming beams for YAG mode and a parfocal aiming beam for SLT mode help the surgeon accurately target pathology.
Nidek has included YAG laser system enhancements to the YC-200/YC-200 S plus that achieve 1.6 mJ plasma threshold in air.* These enhancements allow for robust, homogeneous laser energy delivery. The YC-200 S plus offers an advanced SLT mode that includes SLT-NAVI, which is an intuitive display of the real-time progress of laser treatment. An ergonomic design and optimized working distance minimize surgeon fatigue.
“The suite of technologies incorporated in the YC line of lasers allows surgeons to treat pathology with greater precision,” Motoki Ozawa, President and CEO of Nidek, said in the news release. “The optical and software advances that we have incorporated in the YC lasers ensure safe and efficacious treatments that are delivered ‘Right on the Mark’.”
*A plasma threshold of 1.6 mJ is achieved in ordinary room conditions (in-house data).